Avecho Biotechnology Ltd - Company Profile
Powered by 
All the sales intelligence you need on Avecho Biotechnology Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Avecho Biotechnology Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Avecho Biotechnology Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Avecho Biotechnology Ltd (Avecho) is a research-driven biotechnology firm that develops and commercializes human and animal health products. The company’s product portfolio includes daptomycin, propofol injection, oxymorphone patch, diclofenac gel, oxycodone patch, tretinoin gel and transdermal opioid patches. Its products are used in various applications including injectable dosage forms, feed additives, oral dosage forms, and topical and transdermal dosage forms. Avecho also develops cannabinoid products in partnership with major drug manufacturers. The company markets products under Vital ET, Voveran, Instanac, and TPM brand names. The company collaborates with partners like Novartis and Themis Medicare for product commercialization. It has business presence in Australia, India, Switzerland, France and the US. Avecho is headquartered in Clayton, Victoria, Australia.
Headquarters
Australia
Address
Unit A8, 2a Westall Road, Clayton, Melbourne, Victoria, 3168
Website
www.avecho.com.au
Telephone
61 3 90025000
No of Employees
29
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AVE (ASX)
Revenue (2025)
$797,900
9.3%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-41.5%
(2025 vs 2024)
Market Cap*
$58.1M
Net Profit Margin (2025)
XYZ
-29.5%
(2025 vs 2024)
* As of and is in US$
Avecho Biotechnology Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Vital-ET | TPM |
| Pipeline: | Vital ET |
| Pharmaceutical Cannabinoids: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In August, the company has received a placement to support a landmark clinical study testing its proprietary TPM-enhanced CBD soft-gel capsule for the treatment of insomnia. |
| 2023 | New Products/Services | In June, the company has completed the development of its first edible dosage forms with TPM and Cannabinoids. |
| 2023 | Contracts/Agreements | In May, the company entered into a partnership with Procaps Group to manufacture oral CBD softgel capsules. |
Competitor Comparison
| Key Parameters | Avecho Biotechnology Ltd | Jazz Pharmaceuticals Plc | Little Green Pharma Ltd | Botanix Pharmaceuticals Ltd | Bod Science Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Ireland | Australia | Australia | Australia |
| City | Melbourne | Dublin | Perth | Perth | Sydney |
| State/Province | Victoria | Dublin | Western Australia | Western Australia | New South Wales |
| No. of Employees | 29 | 2,890 | - | 50 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gregory Collier | Chairman | Executive Board | 2020 | - |
| Paul Gavin | Chief Executive Officer | Senior Management | 2020 | - |
| Roksan Libinaki | Chief Operating Officer | Senior Management | 2020 | - |
| Melanie Leydin | Chief Financial Officer; Secretary | Senior Management | - | - |
| Ross Murdoch | Director | Non Executive Board | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer